Frederic Lagarce

List of Publications by Year
in descending order

58 papers	2,598 citations	186265 28 h-index	182427 51 g-index
62 all docs	62 docs citations	62 times ranked	4068 citing authors

#	Article	IF	Citations
1	Serving and studying during COVIDâ€19 pandemic. Clinical Teacher, 2021, 18, 224-225.	0.8	1
2	Specificity of pharmacokinetic modeling of nanomedicines. Drug Discovery Today, 2021, 26, 2259-2268.	6.4	3
3	New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. Pharmaceutical Technology in Hospital Pharmacy, 2021, 6, .	0.4	0
4	Nanomedicines: promises and reality. Drug Discovery Today, 2020, 25, 473-474.	6.4	0
5	GERPAC Consensus Conference â€" Guidance on the Assignment of Microbiological Shelf-life for Hospital Pharmacy Aseptic Preparations. Pharmaceutical Technology in Hospital Pharmacy, 2020, 5, .	0.4	13
6	Methods for the Study of Physical and Chemical Stability and Container-Content Interactions: Report of a GERPAC Workshop. Pharmaceutical Technology in Hospital Pharmacy, 2019, 4, 95-97.	0.4	0
7	Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity . International Journal of Nanomedicine, 2019, Volume 14, 2091-2102.	6.7	6
8	Successful treatment of a recurrent AspergillusÂniger otomycosis with local application of voriconazole. Journal De Mycologie Medicale, 2018, 28, 396-398.	1.5	13
9	Gemcitabine and glioblastoma: challenges and current perspectives. Drug Discovery Today, 2018, 23, 416-423.	6.4	40
10	Quality in Stability Testing. Pharmaceutical Technology in Hospital Pharmacy, 2018, 3, 1-2.	0.4	1
11	After Ten Issues Our Journal Has Found Its Audience and Main Topics. Pharmaceutical Technology in Hospital Pharmacy, 2018, 3, 121-122.	0.4	0
12	Stability of a 50â€†mg/mL Ceftazidime Eye-Drops Formulation. Pharmaceutical Technology in Hospital Pharmacy, 2018, 3, 219-226.	0.4	3
13	Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models. Nanomedicine, 2018, 13, 1999-2013.	3.3	34
14	Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today, 2018, 23, 1936-1949.	6.4	40
15	Models for drug absorption from the small intestine: where are we and where are we going?. Drug Discovery Today, 2017, 22, 761-775.	6.4	85
16	Centrally Prepared Cytotoxic Drugs: What Is the Purpose of Their Quality Control?. Pharmaceutical Technology in Hospital Pharmacy, 2017, 2, .	0.4	2
17	Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicology in Vitro, 2017, 41, 189-199.	2.4	36
18	Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection. Journal of Controlled Release, 2017, 264, 45-54.	9.9	107

#	Article	IF	Citations
19	Quality Assurance in Hospital Pharmacy Compounding Units is a Multi Player Game. Pharmaceutical Technology in Hospital Pharmacy, 2017, 2, .	0.4	0
20	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia. International Journal of Nanomedicine, 2017, Volume 12, 8427-8442.	6.7	16
21	Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats. International Journal of Nanomedicine, 2017, Volume 12, 8159-8170.	6.7	7
22	How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?. Advanced Drug Delivery Reviews, 2016, 106, 320-336.	13.7	78
23	Quality and Safety in the Hospital: The Pharmacist is the Key Person. Pharmaceutical Technology in Hospital Pharmacy, 2016, 1, .	0.4	0
24	Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas. International Journal of Pharmaceutics, 2016, 509, 279-284.	5.2	15
25	Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. Journal of Controlled Release, 2016, 225, 283-293.	9.9	96
26	Nucleic-Acid Delivery Using Lipid Nanocapsules. Current Pharmaceutical Biotechnology, 2016, 17, 723-727.	1.6	15
27	Is the translational approach becoming a reality in nanomedicine?. European Journal of Nanomedicine, 2015, 7, .	0.6	3
28	Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. International Journal of Pharmaceutics, 2015, 481, 154-161.	5.2	82
29	Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discovery Today, 2015, 20, 899-905.	6.4	199
30	<i>In vivo</i> evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor. Nanomedicine, 2015, 10, 589-601.	3.3	39
31	Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide. Drug Discovery Today, 2015, 20, 772-779.	6.4	28
32	Design and stability study of a paediatric oral solution of methotrexate 2mg/ml. International Journal of Pharmaceutics, 2015, 487, 270-273.	5.2	12
33	Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes. International Journal of Pharmaceutics, 2015, 492, 137-140.	5.2	8
34	Combined silencing expression of MGMT with EGFR or galectin-1 enhances the sensitivity of glioblastoma to temozolomide. European Journal of Nanomedicine, 2015, 7, .	0.6	2
35	Nanomedicines: are we lost in translation?. European Journal of Nanomedicine, 2015, 7, .	0.6	3
36	Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. International Journal of Nanomedicine, 2014, 9, 1479.	6.7	22

#	Article	IF	Citations
37	Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: Model of elastomeric portable pumps filled with a fluorouracil solution. Journal of Pharmaceutical and Biomedical Analysis, 2014, 91, 176-184.	2.8	34
38	Mucus models to evaluate nanomedicines for diffusion. Drug Discovery Today, 2014, 19, 1097-1108.	6.4	68
39	Development of 2D and 3D Mucus Models and Their Interactions with Mucus-Penetrating Paclitaxel-Loaded Lipid Nanocapsules. Pharmaceutical Research, 2014, 31, 1753-1765.	3.5	45
40	Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. European Journal of Pharmaceutical Sciences, 2013, 50, 172-180.	4.0	39
41	Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. International Journal of Nanomedicine, 2013, 8, 4291.	6.7	38
42	Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 181-188.	4.3	97
43	Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. International Journal of Nanomedicine, 2011, 6, 2941.	6.7	30
44	Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice. Pharmaceutical Research, 2010, 27, 421-430.	3.5	61
45	Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. European Journal of Pharmaceutical Sciences, 2010, 40, 422-429.	4.0	52
46	Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine, 2010, 5, 287-306.	3.3	264
47	Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. Journal of Controlled Release, 2009, 140, 174-181.	9.9	237
48	The adaptation of lipid nanocapsule formulations for blood administration in animals. International Journal of Pharmaceutics, 2009, 379, 266-269.	5.2	24
49	The gastrointestinal stability of lipid nanocapsules. International Journal of Pharmaceutics, 2009, 379, 260-265.	5.2	82
50	Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 239-246.	4.3	86
51	1208 Toxicity of systemic administration of blank and paclitaxel-loaded lipid nanocapsules in mice. European Journal of Cancer, Supplement, 2009, 7, 123.	2.2	0
52	Development and characterization of interleukin-18-loaded biodegradable microspheres. International Journal of Pharmaceutics, 2006, 314, 179-188.	5.2	25
53	Development of new polymer-based particulate systems for anti-glioma vaccination. International Journal of Pharmaceutics, 2006, 309, 1-5.	5.2	12
54	Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules. Pharmaceutical Research, 2006, 23, 1243-1250.	3.5	258

#	Article	IF	Citations
55	Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model. International Journal of Pharmaceutics, 2005, 298, 68-79.	5.2	6
56	Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 449-459.	4.3	31
57	Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: In vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 61, 171-180.	4.3	41
58	Oxaliplatin loaded PLAGA microspheres:. International Journal of Pharmaceutics, 2002, 242, 243-246.	5.2	24